Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 3Triple Negative Breast Neoplasms 2Melanoma 2Endometrial Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Endometrial Adenocarcinoma 1

Interventions

Ipilimumab 29Nivolumab 23pembrolizumab 14incomplete Freund's adjuvant 10Cyclophosphamide 10Interleukin-2 9Melphalan 8CTLA-4 Antigen 8sargramostim 7Temozolomide 7MART-1 Antigen 7Dacarbazine 7tebentafusp 6Ranibizumab 6montanide ISA 51 5fludarabine phosphate 5fludarabine 5Sunitinib 5Radiosurgery 5Carboplatin 5Bevacizumab 5aldesleukin 4aflibercept 4Magnetic Resonance Spectroscopy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Blood Specimen Collection 4Biopsy 4trametinib 3sotrastaurin 3relatlimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Uveal Melanoma × GSK2141795 × Clear all
NCT01979523 2026-04-13

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
42 enrolled 13 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡